Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP182799.RAQ4vQSDfAuLpQasIx2UfxoYr8gaJZ2A8q4IBOf3CGaZo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP182799.RAQ4vQSDfAuLpQasIx2UfxoYr8gaJZ2A8q4IBOf3CGaZo130_assertion type Assertion NP182799.RAQ4vQSDfAuLpQasIx2UfxoYr8gaJZ2A8q4IBOf3CGaZo130_head.
- NP182799.RAQ4vQSDfAuLpQasIx2UfxoYr8gaJZ2A8q4IBOf3CGaZo130_assertion description "[p53 status should be taken into account when deciding which therapeutic drug to use in glioblastoma multiforme.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP182799.RAQ4vQSDfAuLpQasIx2UfxoYr8gaJZ2A8q4IBOf3CGaZo130_provenance.
- NP182799.RAQ4vQSDfAuLpQasIx2UfxoYr8gaJZ2A8q4IBOf3CGaZo130_assertion evidence source_evidence_literature NP182799.RAQ4vQSDfAuLpQasIx2UfxoYr8gaJZ2A8q4IBOf3CGaZo130_provenance.
- NP182799.RAQ4vQSDfAuLpQasIx2UfxoYr8gaJZ2A8q4IBOf3CGaZo130_assertion SIO_000772 18089819 NP182799.RAQ4vQSDfAuLpQasIx2UfxoYr8gaJZ2A8q4IBOf3CGaZo130_provenance.
- NP182799.RAQ4vQSDfAuLpQasIx2UfxoYr8gaJZ2A8q4IBOf3CGaZo130_assertion wasDerivedFrom lhgdn-20090331 NP182799.RAQ4vQSDfAuLpQasIx2UfxoYr8gaJZ2A8q4IBOf3CGaZo130_provenance.
- NP182799.RAQ4vQSDfAuLpQasIx2UfxoYr8gaJZ2A8q4IBOf3CGaZo130_assertion wasGeneratedBy ECO_0000203 NP182799.RAQ4vQSDfAuLpQasIx2UfxoYr8gaJZ2A8q4IBOf3CGaZo130_provenance.